Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

CRBP Corbus Pharmaceuticals Holdings Inc

Price (delayed)

$7.16

Market cap

$87.62M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.2

Enterprise value

$70.9M

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system. The Company's lead product candidate, lenabasum, is ...

Highlights
CRBP's debt has dropped by 83% year-on-year and by 12% since the previous quarter
The quick ratio has soared by 147% YoY but it fell by 9% QoQ
Corbus Pharmaceuticals Holdings's EPS has increased by 39% YoY but it has decreased by 14% QoQ
Corbus Pharmaceuticals Holdings's net income has decreased by 49% YoY and by 25% from the previous quarter

Key stats

What are the main financial stats of CRBP
Market
Shares outstanding
12.24M
Market cap
$87.62M
Enterprise value
$70.9M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
Gross profit
$0
Operating income
-$58.87M
Net income
-$50.29M
EBIT
-$49.26M
EBITDA
-$48.74M
Free cash flow
-$50.25M
Per share
EPS
-$4.2
EPS diluted
-$4.2
Free cash flow per share
-$4.12
Book value per share
$10.39
Revenue per share
$0
TBVPS
$11.47
Balance sheet
Total assets
$139.93M
Total liabilities
$12.83M
Debt
$2.86M
Equity
$127.11M
Working capital
$125.74M
Liquidity
Debt to equity
0.02
Current ratio
11.82
Quick ratio
11.49
Net debt/EBITDA
0.34
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-32.9%
Return on equity
-36.9%
Return on invested capital
-39.8%
Return on capital employed
-38.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRBP stock price

How has the Corbus Pharmaceuticals Holdings stock price performed over time
Intraday
11.01%
1 week
-3.5%
1 month
18.54%
1 year
-83.34%
YTD
-39.32%
QTD
34.84%

Financial performance

How have Corbus Pharmaceuticals Holdings's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$58.87M
Net income
-$50.29M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 57% year-on-year and by 21% since the previous quarter
Corbus Pharmaceuticals Holdings's net income has decreased by 49% YoY and by 25% from the previous quarter

Price vs fundamentals

How does CRBP's price correlate with its fundamentals

Growth

What is Corbus Pharmaceuticals Holdings's growth rate over time

Valuation

What is Corbus Pharmaceuticals Holdings stock price valuation
P/E
N/A
P/B
0.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Corbus Pharmaceuticals Holdings's EPS has increased by 39% YoY but it has decreased by 14% QoQ
CRBP's P/B is 91% below its 5-year quarterly average of 7.5 and 62% below its last 4 quarters average of 1.8
The company's equity rose by 31% YoY but it fell by 11% QoQ

Efficiency

How efficient is Corbus Pharmaceuticals Holdings business performance
The ROE has soared by 73% YoY but it fell by 18% QoQ
CRBP's return on invested capital is up by 46% year-on-year but it is down by 26% since the previous quarter
The ROA has increased by 43% YoY but it has decreased by 22% from the previous quarter

Dividends

What is CRBP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRBP.

Financial health

How did Corbus Pharmaceuticals Holdings financials performed over time
Corbus Pharmaceuticals Holdings's current ratio has surged by 152% YoY but it has decreased by 9% QoQ
The quick ratio has soared by 147% YoY but it fell by 9% QoQ
CRBP's debt is 98% smaller than its equity
CRBP's debt to equity has dropped by 89% year-on-year
CRBP's debt has dropped by 83% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.